Beta 1 Receptors
Beta 1 Receptors - Related Videos
01:25
Beta
0 Views •
2024
Beta is a crucial metric in finance used to assess an investment's risk and expected return relative to the overall market. It is calculated as the slope of the line in a scatterplot that compares the returns of an individual stock to the returns of the market benchmark, typically represented by a broad market index. Beta quantifies how much a stock's price moves in response to market movements, providing insight into its volatility and systematic risk. A beta of one indicates that the stock's...
07:20
Measuring Erythrocyte Complement Receptor 1 Using Flow Cytometry
0 Views •
Cited by 3 •
2020
The aim of this method is to determine the CR1 density in the erythrocytes of any subject by comparing with three subjects whose erythrocyte CR1 density is known. The method uses flow cytometry after immunostaining of the subjects' erythrocytes by an anti-CR1 monoclonal antibody coupled to an amplified system using phycoerythrin (PE).
08:53
Characterization of pH-Dependent Reversible Self-Assembly of Amyloid Beta 1-40-Coated Gold Colloids
0 Views •
2025
Here, we present a systematic method describing the quasi-reversible self-assembly of the amyloid beta 1-40 (Aβ1-40)-coated 20 nm gold aggregates. The nano-size-dependent quasi-reversible networking between peptides was correlated with specific amino acids or sections of the Aβ1-40 monomer.
01:28
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
0 Views •
2024
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
08:16
Stereotaxic Infusion of Oligomeric Amyloid-beta into the Mouse Hippocampus
0 Views •
Cited by 41 •
2015
Here, we present a protocol for direct stereotaxic brain infusion of amyloid-beta. This methodology provides an alternative in vivo mouse model to address the short-term effects of amyloid-beta on brain neurons.
FAQs
Activation couples the receptor to Gs proteins, which stimulate adenylyl cyclase and raise intracellular cyclic AMP. The resulting increase in protein kinase A signaling enhances cardiac activity, producing faster heart rate and greater contractility. This pathway links sympathetic chemical signals from epinephrine and norepinephrine to changes in cardiac performance and helps explain their effects on cardiac output.
Their distribution connects two complementary control points. In cardiac tissue, activation directly increases heart rate and contractility, whereas receptors in juxtaglomerular kidney cells promote renin release. Cardiac stimulation therefore affects pumping activity, while renal signaling contributes to blood pressure regulation through renin-related control. Considering both locations gives a more complete pharmacological view than focusing on the heart alone.
Cyclic AMP serves as a key intracellular messenger between adenylyl cyclase activation and protein kinase A signaling. When Beta 1 receptor stimulation raises cyclic AMP, downstream signaling supports the increases in heart rate and contractility associated with sympathetic activation. This molecular sequence is important because it explains how an extracellular signal becomes a coordinated cardiovascular response.
Selective Beta 1 blockers reduce the receptor-mediated responses driven by epinephrine and norepinephrine. By limiting signaling associated with increased heart rate, contractility, and renin release, these agents oppose several cardiovascular effects of sympathetic stimulation. Their selectivity makes Beta 1 receptors a focused pharmacological target for reducing cardiovascular workload and regulating blood pressure-related responses.
Agents that reduce Beta 1 receptor effects are used in the management of hypertension, angina, arrhythmias, and selected forms of heart failure. The therapeutic rationale follows from the receptor's contributions to cardiac rate, contractility, and renin release. Reducing these effects can address several cardiovascular problems in which excessive or poorly controlled sympathetic signaling is relevant.
Because activation increases both heart rate and cardiac contractility, Beta 1 signaling can raise the heart's pumping activity and thereby influence cardiac output. The same pathway also stimulates renin release through juxtaglomerular cells, connecting sympathetic receptor activity with blood pressure regulation. Pharmacology uses this relationship to interpret why reducing receptor-mediated effects can alter cardiovascular workload and pressure control.
They provide a mechanistic link between adrenergic stimulation and clinically important cardiovascular outcomes. Their Gs, adenylyl cyclase, cyclic AMP, and protein kinase A pathway offers a defined signaling sequence for understanding drug effects, while their cardiac and renal distribution explains multiple physiological consequences. This combination makes them useful for studying therapies that modify heart function, blood pressure, and related disorders.
The pathway indicates which responses may change when receptor signaling is enhanced or reduced: heart rate, contractility, and renin release. It also identifies the signaling steps involved, from Gs activation through adenylyl cyclase, cyclic AMP, and protein kinase A. Pharmacologists can use this framework to connect a drug's receptor action with anticipated cardiovascular outcomes and therapeutic applications.